AEterna Zentaris (TSX:AEZS) Cash-to-Debt : 126.56 (As of Mar. 2024)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. AEterna Zentaris's cash to debt ratio for the quarter that ended in Mar. 2024 was 126.56.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, AEterna Zentaris could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for AEterna Zentaris's Cash-to-Debt or its related term are showing as below:

TSX:AEZS' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.26 Med: 598.58 Max: No Debt
Current: 126.56

During the past 13 years, AEterna Zentaris's highest Cash to Debt Ratio was No Debt. The lowest was 5.26. And the median was 598.58.

TSX:AEZS's Cash-to-Debt is ranked better than
79.61% of 1486 companies
in the Biotechnology industry
Industry Median: 6.9 vs TSX:AEZS: 126.56

AEterna Zentaris Cash-to-Debt Historical Data

The historical data trend for AEterna Zentaris's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

AEterna Zentaris Cash-to-Debt Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

8.68

131.73

405.75

282.94

121.70

AEterna Zentaris Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															221.98	183.16	178.37	121.70	126.56

Competitive Comparison of AEterna Zentaris's Cash-to-Debt

For the Biotechnology subindustry, AEterna Zentaris's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AEterna Zentaris's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AEterna Zentaris's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where AEterna Zentaris's Cash-to-Debt falls into.

AEterna Zentaris Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

AEterna Zentaris's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	45.636	/	(0.215	+	0.16)
	=	121.70

AEterna Zentaris's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	39.992	/	(0.208	+	0.108)
	=	126.56

AEterna Zentaris (TSX:AEZS) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

AEterna Zentaris Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.